Format

Send to

Choose Destination
Mayo Clin Proc. 2018 Feb;93(2):240-246. doi: 10.1016/j.mayocp.2017.10.022.

Proton Pump Inhibitors: Review of Emerging Concerns.

Author information

1
Department of General Surgery, Mayo Clinic, Rochester, MN.
2
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
3
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. Electronic address: nehra.vandana@mayo.edu.

Abstract

First introduced in 1989, proton pump inhibitors (PPIs) are among the most widely utilized medications worldwide, both in the ambulatory and inpatient clinical settings. The PPIs are currently approved by the US Food and Drug Administration for the management of a variety of gastrointestinal disorders including symptomatic peptic ulcer disease, gastroesophageal reflux disease, and nonulcer dyspepsia as well as for prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. PPIs inhibit gastric acid secretion, and the most commonly associated adverse effects include abdominal pain, diarrhea, and headache. Although PPIs have had an encouraging safety profile, recent studies regarding the long-term use of PPI medications have noted potential adverse effects, including risk of fractures, pneumonia, Clostridium difficile diarrhea, hypomagnesemia, vitamin B12 deficiency, chronic kidney disease, and dementia. These emerging data have led to subsequent investigations to assess these potential risks in patients receiving long-term PPI therapy. However, most of the published evidence is inadequate to establish a definite association between PPI use and the risk for development of serious adverse effects. Hence, when clinically indicated, PPIs can be prescribed at the lowest effective dose for symptom control.

PMID:
29406201
DOI:
10.1016/j.mayocp.2017.10.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center